Repotrectinib Clinical Trials

3 actively recruiting trials across 1 location

▼ -1 trial since June 2026

Also known as: BMS-986472, TPX-0005

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

Memorial Sloan Kettering Cancer Center1
MedSIR1
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer1

Indications

Cancer3
Lung Cancer2
ROS1 Gene Rearrangement1
NSCLC, Stage III1
Advanced Cancer1

Other2 trials

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Phase 2

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Phase 2

New York, New York1 trial

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.